{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:26Z","timestamp":1761512786612},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2010]]},"DOI":"10.2169\/internalmedicine.49.2705","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T06:03:25Z","timestamp":1268633005000},"page":"581-584","source":"Crossref","is-referenced-by-count":11,"title":["Medical Management of Primary Hyperparathyroidism with Concommitant Multiple Myeloma"],"prefix":"10.2169","volume":"49","author":[{"given":"Zaher","family":"Fanari","sequence":"first","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin","family":"Kadikoy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqar","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Pacha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Abdellatif","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine"},{"name":"Division of Nephrology, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Toussirot E, Bille F, Henry JF, Acquaviva PC. Coexisting kappa light chain multiple myeloma and primary hyperparathyroidism. Scand J Rheumatol 23: 49-50, 1994.","DOI":"10.3109\/03009749409102136"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Goto S, Yoshioka M, Nagai K, et al. Primary hyperparathyroidism associated with multiple myeloma. Intern Med 34: 988-991, 1995.","DOI":"10.2169\/internalmedicine.34.988"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rosen C, Segal H, Hartz CE, Mroz F, Carlton E. Primary hyperparathyroidism in an elderly patient with multiple myeloma. J Am Geriatr Soc 40: 703-705, 1992.","DOI":"10.1111\/j.1532-5415.1992.tb01963.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Johansson H, Werner I. Dysproteinemia, malignancy, and hyperparathyroidism. Ann Intern Med 83: 121-122, 1975.","DOI":"10.7326\/0003-4819-83-1-121_2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jackson RM, Orland MJ. Parathyroid adenoma in a patient with multiple myeloma. South Med J 72: 1336-1337, 1979.","DOI":"10.1097\/00007611-197910000-00034"},{"key":"6","unstructured":"6. Chisholm RC, Weaver YJ, Chung EB, Townsend JL. Parathyroid adenoma and light chain myeloma. J Natl Med Assoc 73: 875-880, 1981."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Francis RM, Bynoe AG, Gray C. Hypercalcaemia due to the coexistence of parathyroid adenoma and myelomatosis. J Clin Pathol 35: 732-736, 1982.","DOI":"10.1136\/jcp.35.7.732"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mundis RJ, Kyle RA. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 77: 619-621, 1982.","DOI":"10.1093\/ajcp\/77.5.619"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Stone MJ, Lieberman ZH, Chakmakjian ZH, Matthews JL. Coexistent multiple myeloma and primary hyperparathyroidism. JAMA 247: 823-824, 1982.","DOI":"10.1001\/jama.247.6.823"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hoelzer DR, Silverberg AB. Primary hyperparathyroidism complicated by multiple myeloma. Arch Intern Med 144: 2069-2071, 1984.","DOI":"10.1001\/archinte.1984.04400010196034"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dalgleish AG, Gatenby PA. Refractory hypercalcaemia. Parathyroid adenoma or multiple myeloma? Med J Aust 140: 99-100, 1984.","DOI":"10.5694\/j.1326-5377.1984.tb103906.x"},{"key":"12","unstructured":"12. Tomon M, Fukase M, Nakata M, et al. A case of multiple myeloma associated with primary hyperparathyroidism. Hormone-to-Rinsho 37: 128, 1989 (in Japanese)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schneider W, Thomas M. Hypercalcaemia in coexistent parathyroid adenoma and multiple myeloma: problems of differential diagnosis. Dtsch Med Wochenschr 114: 1199-1202, 1989 (in German).","DOI":"10.1055\/s-2008-1066740"},{"key":"14","unstructured":"14. Rao DS, Antonelli R, Kane KR, Kuhn JE, Hetnal C. Primary hyperparathyroidism and monoclonal gammopathy. Henry Ford Hosp Med J 39: 41-44, 1991."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Rosen C, Segal H, Hartz CE, Mroz F, Carlton E. Primary hyperparathyroidism in an elderly patient with multiple myeloma. J Am Geriatr Soc 40: 703-705, 1992.","DOI":"10.1111\/j.1532-5415.1992.tb01963.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimemetic cincalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644-5649, 2003.","DOI":"10.1210\/jc.2002-021597"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Potts J. Consensus development conference statement. J Bone Miner Res 6: S9-S13, 1991.","DOI":"10.1002\/jbmr.5650061406"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27: 1725-1751, 2005.","DOI":"10.1016\/j.clinthera.2005.11.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37: 915-922, 2007.","DOI":"10.1111\/j.1365-2362.2007.01874.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 10: 97-103, 1999.","DOI":"10.1385\/ENDO:10:2:97"},{"key":"21","unstructured":"21. Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290: 473-479, 1999."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rossini M, Gatti D, Isaiah G, Sartori L, Braga V, Adami S. Effects of oral aldronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16: 113-119, 2001.","DOI":"10.1359\/jbmr.2001.16.1.113"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032-1045, 2008.","DOI":"10.4065\/83.9.1032"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/49\/6\/49_6_581\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:59:35Z","timestamp":1591145975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/49\/6\/49_6_581\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.49.2705","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}